ストックスクリーナーアプリを入手
11.61
2.20%
0.25
アフターアワーズ：
11.50
-0.11
-0.95%
前日終値:
$11.36
開ける：
$11.65
24時間の取引高:
1.13M
Relative Volume:
0.64
時価総額：
$1.32B
収益：
$655.35M
当期純損益:
$-136.23M
株価収益率:
-9.4985
EPS:
-1.2223
ネットキャッシュフロー:
$-75.68M
1週間 パフォーマンス:
-3.73%
1か月 パフォーマンス:
-22.55%
6か月 パフォーマンス:
-9.15%
1年 パフォーマンス:
-38.15%
1日の値動き範囲:
$11.47
$11.83
1週間の範囲:
$11.24
$12.37
52週間の値動き範囲:
$9.82
$20.06
Novocure Ltd Stock (NVCR) Company Profile
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
11.61 | 1.29B | 655.35M | -136.23M | -75.68M | -1.2223 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2024-12-02 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-10-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 開始されました | SVB Securities | Outperform |
| 2023-07-31 | アップグレード | Evercore ISI | Underperform → In-line |
| 2023-06-07 | アップグレード | Wedbush | Underperform → Neutral |
| 2023-05-16 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-01-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-11-29 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-08 | 開始されました | Loop Capital | Buy |
| 2022-02-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2022-01-03 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-07-01 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-14 | ダウングレード | Wedbush | Neutral → Underperform |
| 2021-01-25 | 繰り返されました | Piper Sandler | Overweight |
| 2020-09-23 | 開始されました | Northland Capital | Outperform |
| 2020-09-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | ダウングレード | Truist | Buy → Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Perform |
| 2020-05-01 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-04-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2020-03-05 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-07-29 | アップグレード | SunTrust | Hold → Buy |
| 2019-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-07-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Hold |
| 2018-11-02 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 開始されました | Evercore ISI | Outperform |
| 2018-04-18 | 繰り返されました | Mizuho | Buy |
| 2018-02-23 | 繰り返されました | Mizuho | Buy |
| 2017-05-24 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 繰り返されました | Wedbush | Outperform |
| 2016-01-19 | 開始されました | Barclays | Underweight |
| 2015-12-02 | 開始されました | Deutsche Bank | Hold |
すべてを表示
Novocure Ltd (NVCR) 最新ニュース
Tudor Investment Corp ET AL Purchases 354,216 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Limited $NVCR Position Lifted by Algert Global LLC - MarketBeat
Capital World Investors Lowers Holdings in NovoCure Limited $NVCR - MarketBeat
FDA Approves Novocure’s Optune Pax Wearable Device for Pancreatic Cancer - Digital Health News
NovoCure Limited $NVCR Shares Acquired by American Century Companies Inc. - MarketBeat
Novocure at Leerink Conference: Strategic Growth in Cancer Treatment By Investing.com - Investing.com South Africa
Novocure at Leerink Conference: Strategic Growth in Cancer Treatment - Investing.com Australia
Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story? - Sahm
Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment - Yahoo Finance
Assessing Novocure (NVCR) Valuation After Japan Reimbursement Approval For Optune Lua - Sahm
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Insider Selling: NovoCure (NASDAQ:NVCR) Insider Sells 1,100 Shares of Stock - MarketBeat
NovoCure (NASDAQ:NVCR) CFO Sells $85,343.72 in Stock - MarketBeat
NovoCure (NASDAQ:NVCR) CEO Sells $74,629.17 in Stock - MarketBeat
Mukund Paravasthu Sells 5,377 Shares of NovoCure (NASDAQ:NVCR) Stock - MarketBeat
NovoCure (NASDAQ:NVCR) COO Mukund Paravasthu Sells 43,246 Shares - MarketBeat
NVCR Crosses Above Key Moving Average Level - Nasdaq
NovoCure (NVCR) General Counsel receives new stock options and RSU grants - Stock Titan
NovoCure (NASDAQ: NVCR) CMO reports tax sale and new stock awards - Stock Titan
[144] NovoCure Ltd SEC Filing - Stock Titan
NVCR (NASDAQ) Form 144: Insider-related sales include 3,272 and 7,461 shares - Stock Titan
NovoCure Ltd. Hits Day Low of $11.80 Amid Price Pressure - Markets Mojo
Vanguard Group Inc. Sells 296,555 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Limited $NVCR Shares Bought by Quantbot Technologies LP - MarketBeat
NovoCure (NVCR) CMO sells shares to cover RSU tax withholding - Stock Titan
NovoCure (NVCR) CHRO sells 1,441 shares in tax withholding trade - Stock Titan
NovoCure (NVCR) COO offloads 1,963 shares in tax sell-to-cover - Stock Titan
Tax-withholding sale of 1,029 NovoCure (NASDAQ: NVCR) shares by ex-CMO - Stock Titan
NovoCure (NVCR) CEO reports RSU vesting and tax-cover share sales - Stock Titan
Equity awards and tax share withholding for NovoCure (NVCR) ex-CEO Cordova - Stock Titan
NovoCure (NASDAQ: NVCR) General Counsel receives 17,755-share performance award - Stock Titan
NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update - Sahm
Novocure gains Japan reimbursement for Optune Lua device - Investing.com Australia
NovoCure Limited 2025 Q4ResultsEarnings Call Presentation (NASDAQ:NVCR) 2026-03-02 - Seeking Alpha
NovoCure Ltd wins Japanese reimbursement approval for lung cancer treatment - Traders Union
NovoCure (NVCR) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Novocure (NVCR) Gains Japanese Reimbursement Approval for Optune Lua - GuruFocus
Novocure (NVCR) Gains Approval for Optune Lua Reimbursement in J - GuruFocus
Novocure gains Japan reimbursement for Optune Lua device By Investing.com - Investing.com Canada
Japan’s health system to cover wearable lung cancer device Optune Lua - Stock Titan
NovoCure Earnings Call: Growth Builds Amid Profit Strain - The Globe and Mail
Equities Analysts Set Expectations for NovoCure Q1 Earnings - MarketBeat
A Look At NovoCure (NVCR) Valuation As Record 2025 Results And Optune Pax Approval Reset Growth Expectations - Yahoo Finance
NovoCure Ltd. Opens with 6.47% Gain, Outpacing S&P 500's 0.69% Rise - Markets Mojo
NovoCure Shares Gap Down, Weak Start Raises Market Concerns - Markets Mojo
NovoCure Ltd. Hits Day High with 27.68% Surge in Stock Price - Markets Mojo
NovoCure Ltd. Experiences Revision in Stock Evaluation Amidst Market Challenges - Markets Mojo
Is NovoCure (NVCR) Pricing Look Out Of Step With Recent Share Rebound - simplywall.st
NovoCure’s Pancreatic Cancer Approval And New CEO Shift Risk Reward Profile - simplywall.st
Hohimer Wealth Management LLC Takes Position in NovoCure Limited $NVCR - MarketBeat
Novocure CEO and CFO to field investor questions at Leerink event - Stock Titan
Novocure Ltd (NVCR) 財務データ
収益
当期純利益
現金流量
EPS
1.53%
大文字化:
|
ボリューム (24 時間):